Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection
HANGZHOU and SHAOXING, China, Sept. 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection has completed ...
Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
-- Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a new and differentiated chemical...
Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
-- Enrollment of the total 12 subjects is expected to be completed in August 2022 -- The DDI study on ASC42 in the U.S. is expected to be completed by the beginning of the fourth quarter 2022 -- This DDI study and ongoing Phase II clinical trial in PBC patients in China will provide more eviden...
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors
--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFNγ in a concentration dependent manner with an EC50 of 2.86 nM. Ma...
Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA
HANGZHOU, China and SHAOXING, China, Aug. 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the Investigational New Drug (IND) application of ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19, has been accep...
Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients
-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active metabolite ASC10-A, which is the same active metabolite of molnupiravir -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a n...
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and Ascletis retains full global rights for its development and commercialization --This IND filing of ASC10 in the U.S. will accelerate Ascletis' global multi-center clinical studies on ASC10 and bett...
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
HANGZHOU and SHAOXING, China, July 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection, which was initiated by Shangh...
Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection
-- The Phase II clinical study in China is currently expected to be completed in early 2023 with an expected enrollment of 30 subjects HANGZHOU, China and SHAOXING, China, June 28, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the first subject has been ...
Ascletis' Subcutaneous PD-L1 Antibody ASC22 Demonstrated Potential of Functional Cure of Chronic Hepatitis B as 42.9% of Patients with Baseline HBsAg≤100 IU/mL Obtained Sustained HBsAg Loss
--Ascletis presented Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 for functional cure of CHB at oral session of EASL ILC 2022 on June 25, 2022, Beijing Time --The Phase IIb clinical trial results further demonstrated the potential of ASC22+NAs treatment as a functional cu...
Ascletis Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022
- The updates of ASC22 Phase IIb study will be presented at the oral session during the International Liver Congress™ 2022 onSaturday, June 25, 2022 at 14:15 , Beijing Time (Abstract Number: OS091) HANGZHOU, China and SHAOXING, China, June 16, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672...
Ascletis Announces Appointment of Mr. John P. Gargiulo, Former North America President and CEO of Daiichi Sankyo, as Chief Business Officer
HANGZHOU, China and SHAOXING, China, June 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), today announces the expansion of management team with appointment of Mr.John P. Gargiulo, former North America President and CEO of Daiichi Sankyo, as Chief Business Officer. Mr.John ...
Gannex Announces U.S. FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
-- ASC42 has completed Phase I trials in the U.S. and China. This approval from U.S. FDA enables Gannex to complete a critical drug-drug interaction (DDI) study to support upcoming Phase III trials inChina, the U.S. and European Union -- Gannex expects to complete this DDI study at the beginning ...
Ascletis (1672.HK) Included in MSCI China Small Cap Index
HANGZHOU and SHAOXING, China, May 16, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the MSCI China Small Cap Index, effective after the market close onMay 31, 2022. Morgan Stanley Capital International (MSCI) is a leading provider o...
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients
HANGZHOU, China and SHAOXING, China, May 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND) application approval of ASC22 (Envafolimab) by U.S. Food and Drug Administration (FDA) for the indication of immune restoration/functi...
Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19
- In antiviral cellular assays, antiviral potency (EC90) of ASC11 is 31-fold of that of Nirmatrelvir, 120-fold of that of S-217622, 16-fold of that of PBI-0451 and 7-fold of that of EDP-235. - ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3CLpro, with global intel...
Ascletis Announces Cooperation with China Meheco International Co., Ltd. in Distribution of Its Ritonavir Tablets in Chinese Mainland
HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Ascletis Pharmaceuticals Co., Ltd. ("Ascletis Pharmaceuticals") has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavi...
Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
-- Gannex is expected to complete the Phase II trial in 100 patients by the end of 2022. -- Gannex intends to soon start a Phase III trial in China, the U.S. and European Union after the completion of the Phase II study inChina. -- An epidemiology study in China in 2010 showed that there were a...
Ascletis Announces China IND Approval of Its Second FASN Inhibitor ASC60 for Treatment of Advanced Solid Tumors
HANGZHOU, China and SHAOXING, China, April 6, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that the Investigational New Drug (IND) application of its second fatty acid synthase (FASN) inhibitor ASC60 for treatment of advanced solid tumors has been approved by China ...
Ascletis Announces Completion of First Sale of Its Ritonavir Tablets in Zhejiang Province
HANGZHOU, China and SHAOXING, China, April 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that the first sale of its ritonavir tablets inZhejiang Province has been completed. On April 3, 2022, Ascletis' distributor, Zhejiang Int'l Medicine Co., Ltd. ("Zhejiang Int'l"),...
